EMA Application withdrawn: Asimtufii (aripiprazole monohydrate) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

The EMA has withdrawn the application for Asimtufii (aripiprazole monohydrate) by Otsuka Pharmaceutical Netherlands B.V. for schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Asimtufii (aripiprazole monohydrate)

Snippet

Status: Application withdrawn. Therapeutic area: Schizophrenia. MAH: Otsuka Pharmaceutical Netherlands B.V.